PTC Therapeutics Inc (PTCT) — Cash Flow-to-Debt Ratio
PTC Therapeutics Inc (PTCT) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-59.04 Million could theoretically repay 0% of its total liabilities ($3.05 Billion) in one year. Check how aggressively does PTC Therapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PTC Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for PTC Therapeutics Inc across 15 annual periods. Also explore how large is PTC Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for PTC Therapeutics Inc (2011–2025)
Year-by-year debt coverage analysis for PTC Therapeutics Inc. For market capitalisation and broader financial context, see PTC Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | $711.20 Million | $3.12 Billion | ▲ +694.0% |
| 2024 | -0.04x | $-107.69 Million | $2.80 Billion | ▲ +34.2% |
| 2023 | -0.06x | $-158.42 Million | $2.71 Billion | ▲ +66.4% |
| 2022 | -0.17x | $-356.65 Million | $2.05 Billion | ▼ -33.9% |
| 2021 | -0.13x | $-251.33 Million | $1.94 Billion | ▼ -15.4% |
| 2020 | -0.11x | $-194.07 Million | $1.73 Billion | ▼ -17.3% |
| 2019 | -0.10x | $-98.64 Million | $1.03 Billion | ▼ -166.4% |
| 2018 | -0.04x | $-27.64 Million | $768.50 Million | ▲ +15.9% |
| 2017 | -0.04x | $-10.06 Million | $235.22 Million | ▲ +93.8% |
| 2016 | -0.69x | $-103.57 Million | $149.76 Million | ▲ +61.3% |
| 2015 | -1.79x | $-124.34 Million | $69.57 Million | ▼ -8.4% |
| 2014 | -1.65x | $-57.27 Million | $34.75 Million | ▲ +46.0% |
| 2013 | -3.05x | $-46.92 Million | $15.36 Million | ▼ -105.7% |
| 2012 | -1.49x | $-47.93 Million | $32.27 Million | ▼ -1922.4% |
| 2011 | -0.07x | $-20.77 Million | $282.75 Million | — |